Melatonin reduces oxidative stress and improves vascular function in pulmonary hypertensive newborn sheep

Journal of Pineal Research

Volumn 58, Issue 3, 2015, Pages 362-373

  Torres, Flavio ^a   González Candia, Alejandro ^a   Montt, Camilo ^a   Ebensperger, Germán ^a   Chubretovic, Magdalena ^a   Serõn Ferré, María ^a   Reyes, Roberto V ^a   Llanos, Aníbal J ^a,b   Herrera, Emilio A ^a,b  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

antioxidant system; chronic hypoxia; nitric oxide; oxidative stress; pulmonary hypoxic vasoconstriction; vascular function

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEMOGLOBIN; MELATONIN; NITRIC OXIDE; OXYGEN; ANTIOXIDANT;

ALTITUDE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTERIAL OXYGEN TENSION; ARTICLE; BIOAVAILABILITY; BLOOD VESSEL FUNCTION; BLOOD VESSEL REACTIVITY; CARBON DIOXIDE TENSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; EXPERIMENTAL SHEEP; HEMOGLOBIN BLOOD LEVEL; LUNG PARENCHYMA; LUNG PRESSURE; LUNG RESISTANCE; MORPHOMETRICS; MYOGRAPHY; NEWBORN; NEWBORN DISEASE; NONHUMAN; OXIDATIVE STRESS; OXYGEN CONCENTRATION; OXYGEN TENSION; PRESSURE; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; PULMONARY HYPERTENSION OF THE NEWBORN; TREATMENT DURATION; VASODILATATION; ANIMAL; DRUG EFFECTS; LUNG; METABOLISM; PHYSIOLOGY; SHEEP; VASCULARIZATION;

ANIMALS; ANIMALS, NEWBORN; ANTIOXIDANTS; HYPERTENSION, PULMONARY; LUNG; MELATONIN; OXIDATIVE STRESS; PULMONARY ARTERY; SHEEP;

EID: 84924664168     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12222     Document Type: Article

References (76)

1. Moore LG, Shriver M, Bemis L, et al. Maternal adaptation to high-altitude pregnancy: an experiment of nature-a review. Placenta 2004; 25 (Suppl A): S60-S71.
2. Basnyat B, Murdoch DR,. High-altitude illness. Lancet 2003; 361: 1967-1974.
3. Penaloza D, Arias-Stella J,. The heart and pulmonary circulation at high altitudes: healthy highlanders and chronic mountain sickness. Circulation 2007; 115: 1132-1146.
4. Rudolph AM,. Fetal and neonatal pulmonary circulation. Annu Rev Physiol 1979; 41: 383-395.
5. Walsh-Sukys MC, Tyson JE, Wright LL, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000; 105: 14-20.
6. Keyes LE, Armaza JF, Niermeyer S, et al. Intrauterine growth restriction, preeclampsia, and intrauterine mortality at high altitude in Bolivia. Pediatr Res 2003; 54: 20-25.
7. de Meer K, Heymans HS, Zijlstra WG,. Physical adaptation of children to life at high altitude. Eur J Pediatr 1995; 154: 263-272.
8. Niermeyer S, Andrade Mollinedo P, Huicho L,. Child health and living at high altitude. Arch Dis Child 2009; 94: 806-811.
9. Giussani DA, Davidge ST,. Developmental programming of cardiovascular disease by prenatal hypoxia. J Dev Orig Health Dis 2013; 4: 328-337.
10. Niermeyer S,. Cardiopulmonary transition in the high altitude infant. High Alt Med Biol 2003; 4: 225-239.
11. Steinhorn RH,. Neonatal pulmonary hypertension. Pediatr Crit Care Med 2010; 11: S79-S84.
12. Gao Y, Raj JU,. Regulation of the pulmonary circulation in the fetus and newborn. Physiol Rev 2010; 90: 1291-1335.
13. Gao Y, Raj JU,. Hypoxic pulmonary hypertension of the newborn. Compr Physiol 2011; 1: 61-79.
14. Gamboa R, Marticorena E,. Pulmonary arterial pressure in newborn infants in high altitude. Arch Inst Biol Andina 1971; 4: 55-66.
15. Stenmark KR, Fasules J, Hyde DM, et al. Severe pulmonary hypertension and arterial adventitial changes in newborn calves at 4300 m. J Appl Physiol 1987; 62: 821-830.
16. Herrera EA, Pulgar VM, Riquelme RA, et al. High-altitude chronic hypoxia during gestation and after birth modifies cardiovascular responses in newborn sheep. Am J Physiol Regul Integr Comp Physiol 2007; 292: 2234-2240.
17. Herrera EA, Riquelme RA, Ebensperger G, et al. Long-term exposure to high-altitude chronic hypoxia during gestation induces neonatal pulmonary hypertension at sea level. Am J Physiol Regul Integr Comp Physiol 2010; 299: 1676-1684.
18. Sylvester JT, Shimoda LA, Aaronson PI, et al. Hypoxic pulmonary vasoconstriction. Physiol Rev 2012; 92: 367-520.
19. Sies H,. Oxidative stress: from basic research to clinical application. Am J Med 1991; 91: 31S-38S.
20. Guzy RD, Schumacker PT,. Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Exp Physiol 2006; 91: 807-819.
21. 2+ release and PKC. Free Radic Biol Med 2008; 45: 1468-1476.
22. 2+ release. Antioxid Redox Signal 2000; 2: 47-54.
23. Choi SL, Kim SJ, Lee KT, et al. The regulation of AMP-activated protein kinase by H(2)O(2). Biochem Biophys Res Commun 2001; 287: 92-97.
24. Farrow KN, Wedgwood S, Lee KJ, et al. Mitochondrial oxidant stress increases PDE5 activity in persistent pulmonary hypertension of the newborn. Respir Physiol Neurobiol 2010; 174: 272-281.
25. Fortuno A, San Jose G, Moreno MU, et al. Oxidative stress and vascular remodelling. Exp Physiol 2005; 90: 457-462.
26. Cai H, Harrison DG,. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-844.
27. Miller SL, Wallace EM, Walker DW,. Antioxidant therapies: a potential role in perinatal medicine. Neuroendocrinology 2012; 96: 13-23.
28. Tan DX, Hardeland R, Manchester LC, et al. Mechanistic and comparative studies of melatonin and classic antioxidants in terms of their interactions with the ABTS cation radical. J Pineal Res 2003; 34: 249-259.
29. Buonocore G, Groenendaal F,. Anti-oxidant strategies. Semin Fetal Neonatal Med 2007; 12: 287-295.
30. Aversa S, Pellegrino S, Barberi I, et al. Potential utility of melatonin as an antioxidant during pregnancy and in the perinatal period. J Matern Fetal Neonatal Med 2012; 25: 207-221.
31. Gitto E, Marseglia L, Manti S, et al. Protective role of melatonin in neonatal diseases. Oxid Med Cell Longev 2013; 2013: 980374.
32. Herrera EA, Macchiavello R, Montt C, et al. Melatonin improves cerebrovascular function and decreases oxidative stress in chronically hypoxic lambs. J Pineal Res 2014; 57: 33-42.
33. Reiter RJ, Tan DX, Mayo JC, et al. Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans. Acta Biochim Pol 2003; 50: 1129-1146.
34. Rodriguez C, Mayo JC, Sainz RM, et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004; 36: 1-9.
35. Galano A, Tan DX, Reiter RJ,. On the free radical scavenging activities of melatonin's metabolites. AFMK and AMK. J Pineal Res 2013; 54: 245-257.
36. Weekley LB,. Effects of melatonin on isolated pulmonary artery and vein: role of the vascular endothelium. Pulm Pharmacol 1993; 6: 149-154.
37. Das R, Balonan L, Ballard HJ, et al. Chronic hypoxia inhibits the antihypertensive effect of melatonin on pulmonary artery. Int J Cardiol 2008; 126: 340-345.
38. Claypool LE, Wood RI, Yellon SM, et al. The ontogeny of melatonin secretion in the lamb. Endocrinology 1989; 124: 2135-2143.
39. Seron-Ferre M, Torres-Farfan C, Forcelledo ML, et al. The development of circadian rhythms in the fetus and neonate. Semin Perinatol 2001; 25: 363-370.
40. Wu DC, Zhang HD, Jing ZC,. Pediatric pulmonary arterial hypertension. Curr Hypertens Rep 2013; 15: 606-613.
41. Nair J, Lakshminrusimha S,. Update on PPHN: mechanisms and treatment. Semin Perinatol 2014; 38: 78-91.
42. Jahnke G, Marr M, Myers C, et al. Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats. Toxicol Sci 1999; 50: 271-279.
43. Herrera EA, Verkerk MM, Derks JB, et al. Antioxidant treatment alters peripheral vascular dysfunction induced by postnatal glucocorticoid therapy in rats. PLoS ONE 2010; 5: e9250.
44. Işcan Y, Yiʇit U, Tuʇcu BÇ, et al. Tear nitric oxide levels in Behçet's disease. Medicina (Kaunas) 2012; 48: 559-562.
45. Ebensperger G, Ebensperger R, Herrera EA, et al. Fetal brain hypometabolism during prolonged hypoxaemia in the llama. J Physiol 2005; 567: 963-975.
46. Herrera EA, Reyes RV, Giussani DA, et al. Carbon monoxide: a novel pulmonary artery vasodilator in neonatal llamas of the Andean altiplano. Cardiovasc Res 2008; 77: 197-201.
47. Szymczyk G, Bełtowski J, Marciniak A, et al. Serum isoprostanes levels in patients after abdominal hysterectomy. Rocz Akad Med Bialymst 2005; 50: 322-324.
48. Peddireddy V, Siva Prasad B, Gundimeda SD, et al. Assessment of 8-oxo-7, 8-dihydro-2′-deoxyguanosine and malondialdehyde levels as oxidative stress markers and antioxidant status in non-small cell lung cancer. Biomarkers 2012; 17: 261-268.
49. Benzie IF, Strain JJ,. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem 1996; 239: 70-76.
50. Thakor AS, Herrera EA, Seron-Ferre M, et al. Melatonin and vitamin C increase umbilical blood flow via nitric oxide-dependent mechanisms. J Pineal Res 2010; 49: 399-406.
51. Herrera EA, Ebensperger G, Krause BJ, et al. Sildenafil reverses hypoxic pulmonary hypertension in highland and lowland newborn sheep. Pediatr Res 2008; 63: 169-175.
52. Sime F, Banchero N, Penaloza D, et al. Pulmonary hypertension in children born and living at high altitudes. Am J Cardiol 1963; 11: 143-149.
53. Girouard H, Chulak C, Lejossec M, et al. Vasorelaxant effects of the chronic treatment with melatonin on mesenteric artery and aorta of spontaneously hypertensive rats. J Hypertens 2001; 19: 1369-1377.
54. Huie RE, Padmaja S,. The reaction of NO with superoxide. Free Radic Res Commun 1993; 18: 195-199.
55. Lopez A, Garcia JA, Escames G, et al. Melatonin protects the mitochondria from oxidative damage reducing oxygen consumption, membrane potential, and superoxide anion production. J Pineal Res 2009; 46: 188-198.
56. Lundberg JO, Weitzberg E, Gladwin MT,. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 2008; 7: 156-167.
57. Belik J, Jankov RP, Pan J, et al. Peroxynitrite inhibits relaxation and induces pulmonary artery muscle contraction in the newborn rat. Free Radic Biol Med 2004; 37: 1384-1392.
58. Dubocovich ML, Markowska M,. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005; 27: 101-110.
59. Leon J, Acuna-Castroviejo D, Sainz RM, et al. Melatonin and mitochondrial function. Life Sci 2004; 75: 765-790.
60. Chen YC, Tain YL, Sheen JM, et al. Melatonin utility in neonates and children. J Formos Med Assoc 2012; 111: 57-66.
61. Okatani Y, Wakatsuki A, Kaneda C,. Melatonin increases activities of glutathione peroxidase and superoxide dismutase in fetal rat brain. J Pineal Res 2000; 28: 89-96.
62. Reiter RJ, Tan DX, Osuna C, et al. Actions of melatonin in the reduction of oxidative stress. A review. J Biomed Sci 2000; 7: 444-458.
63. Taskiran D, Tanyalcin T, Sozmen EY, et al. The effects of melatonin on the antioxidant systems in experimental spinal injury. Int J Neurosci 2000; 104: 63-73.
64. Reiter RJ, Acuna-Castroviejo D, Tan DX, et al. Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system. Ann N Y Acad Sci 2001; 939: 200-215.
65. Mayo JC, Sainz RM, Antoli I, et al. Melatonin regulation of antioxidant enzyme gene expression. Cell Mol Life Sci 2002; 59: 1706-1713.
66. Tomas-Zapico C, Coto-Montes A, Martinez-Fraga J, et al. Effects of delta-aminolevulinic acid and melatonin in the harderian gland of female Syrian hamsters. Free Radic Biol Med 2002; 32: 1197-1204.
67. Gurlek A, Aydogan H, Parlakpinar H, et al. Protective effect of melatonin on random pattern skin flap necrosis in pinealectomized rat. J Pineal Res 2004; 36: 58-63.
68. Chan AS, Lai FP, Lo RK, et al. Melatonin mt1 and MT2 receptors stimulate c-Jun N-terminal kinase via pertussis toxin-sensitive and -insensitive G proteins. Cell Signal 2002; 14: 249-257.
69. Benitez-King G, Huerto-Delgadillo L, Anton-Tay F,. Binding of 3H-melatonin to calmodulin. Life Sci 1993; 53: 201-207.
70. Vanecek J,. Cellular mechanisms of melatonin action. Physiol Rev 1998; 78: 687-721.
71. Ross AW, Barrett P, Mercer JG, et al. Melatonin suppresses the induction of AP-1 transcription factor components in the pars tuberalis of the pituitary. Mol Cell Endocrinol 1996; 123: 71-80.
72. Gilad E, Wong HR, Zingarelli B, et al. Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NFkappaB activation. FASEB J 1998; 12: 685-693.
73. Urata Y, Honma S, Goto S, et al. Melatonin induces gamma-glutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells. Free Radic Biol Med 1999; 27: 838-847.
74. Kwon KJ, Kim JN, Kim MK, et al. Melatonin synergistically increases resveratrol-induced heme oxygenase-1 expression through the inhibition of ubiquitin-dependent proteasome pathway: a possible role in neuroprotection. J Pineal Res 2011; 50: 110-123.
75. Jin H, Wang Y, Zhou L, et al. Melatonin attenuates hypoxic pulmonary hypertension by inhibiting the inflammation and the proliferation of pulmonary arterial smooth muscle cells. J Pineal Res 2014; 57: 442-450.
76. Poggi C, Dani C,. Antioxidant strategies and respiratory disease of the preterm newborn: an update. Oxid Med Cell Longev 2014; 2014: 721043.